BioDelivery Sciences International (BDSI) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of BioDelivery Sciences International (NASDAQ:BDSI) from a hold rating to a sell rating in a report published on Tuesday, BidAskClub reports.

Several other brokerages have also weighed in on BDSI. Janney Montgomery Scott reaffirmed a buy rating and set a $5.00 price objective on shares of BioDelivery Sciences International in a research report on Thursday, January 31st. Zacks Investment Research lowered shares of BioDelivery Sciences International from a strong-buy rating to a hold rating in a research report on Friday, January 11th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a buy rating in a research report on Friday, January 25th. SunTrust Banks initiated coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They set a buy rating and a $7.00 price objective on the stock. Finally, HC Wainwright reaffirmed a buy rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a research report on Friday, March 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $5.79.

NASDAQ BDSI opened at $4.85 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. BioDelivery Sciences International has a 52-week low of $1.70 and a 52-week high of $5.37.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $18.03 million during the quarter, compared to analyst estimates of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. As a group, analysts predict that BioDelivery Sciences International will post -0.23 EPS for the current fiscal year.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 9,050 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $5.20, for a total transaction of $47,060.00. Following the transaction, the director now owns 2,509,005 shares in the company, valued at $13,046,826. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $5.07, for a total value of $116,610.00. Following the transaction, the director now owns 544,187 shares in the company, valued at approximately $2,759,028.09. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,048,050 shares of company stock worth $10,241,990. Insiders own 13.26% of the company’s stock.

A number of hedge funds have recently made changes to their positions in BDSI. Advisor Group Inc. grew its holdings in BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares during the last quarter. Means Investment CO. Inc. acquired a new position in BioDelivery Sciences International during the first quarter valued at approximately $59,000. Squarepoint Ops LLC acquired a new position in BioDelivery Sciences International during the fourth quarter valued at approximately $147,000. Raymond James & Associates grew its holdings in BioDelivery Sciences International by 14.9% during the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in BioDelivery Sciences International during the third quarter valued at approximately $255,000. Institutional investors own 57.09% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: What do I need to know about analyst ratings?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit